Today, on 14 November 2019, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. All...
Ascelia Pharma AB (publ) (ticker: ACE) today published its first quarter interim report for the period July 2019 – September 2019, which is ...
Ascelia Pharma AB (publ) today announced that Ascelia Pharma and the company’s Chief Operation Officer (COO) Dorthe da Graça Thrige have rea...
The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797, are hereby invited to attend the annual general meeting (Sw. årsstämma) to be h...
Ascelia Pharma's Annual Report for the financial year 2018/2019 has today been published on the company's website www.ascelia.com
On 12th of September, Ascelia Pharma’s CEO Magnus Corfitzen will present the latest development in the company at Redeye’s afterwork event i...
On 10th of September, Ascelia Pharma's CEO Magnus Corfitzen will present the latest development in the company at Operaterassen in Stockholm...
Ascelia Pharma AB (publ) (ticker: ACE) today announced that its full-year report for the period July 2018 - June 2019 is now available on th...
Ascelia Pharma’s full-year report for the period July 2018 – June 2019 (FY 2018/2019) will be published on Thursday 22 August 2019 at 09:00 ...
Today, Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) announces that it has filed a patent application for a next generation Mangoral pr...
